ClinicalTrials.gg

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Program

tezepelumab

Also written as “Tezepelumab”, “Experimental: Tezepelumab” and “MEDI9929”.

Its studies are mostly in Asthma · Pulmonary Disease, Chronic Obstructive · Dermatitis, Atopic · Nasal Polyps · Rhinosinusitis, led by 3 companies.

Drug pageTezepelumab: every studyAll 48 studies of it, academic ones too, with its approvals, label and forms.
Furthest: phase 4, since Mar 17, 202234 company-led studies, 9 open or runningNext primary completion: Jan 13, 2027 (phase 3)

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
AstraZeneca288 open or runningphase 4since Mar 17, 2022Jul 30, 2013Jan 13, 2027phase 3 · NCT06706817
Amgenits history only50 open or runningphase 2since Jan 10, 2019Sep 18, 2008none ahead
Qilu Pharmaceuticalits history only11 open or runningphase 3since Dec 11, 2025Dec 11, 2025Dec 2028phase 3 · NCT07302516

Also a collaborator on its studies: Fortrea and Parexel.

How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.

History and studies of AstraZeneca only; the figures above count every company.

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). An open circle marks the day WHO proposed its name. Dates ahead are the sponsors’ estimates.

Not listed one by one: 13 earlier studies, Jul 30, 2013 to Jul 29, 2019.

  1. Jun 9, 2015Named tezepelumabINNProposed as its International Nonproprietary Name in WHO's List 113 · before, MEDI9929
  2. Apr 23, 2020Phase 1 study in Healthy SubjectsNCT04362410 · 48 enrolled · China
  3. Dec 2, 2020Phase 1 study in AsthmaNCT04673630 · 18 enrolled · Hungary, South Africa, United Kingdom
  4. Feb 18, 2021Phase 3 study in Nasal PolypsNCT04851964 · 416 enrolled · United States, Canada, China and more
  5. Aug 23, 2021Phase 3 study in Moderate to Severe AsthmaNCT05062759 · 70 enrolled · United States
  6. Jan 27, 2022Phase 3 study in AsthmaNCT05274815 · 305 enrolled · United States, Argentina, Belgium and more
  7. Mar 17, 2022Phase 4 study in AsthmaNCT05329194 · 286 enrolled · United States
  8. May 26, 2022Phase 3 study in AsthmaNCT05398263 · 125 enrolled · United States, Brazil, Canada and more
  9. Oct 13, 2022Phase 3 study in Eosinophilic EsophagitisNCT05583227 · 368 enrolled · United States, Australia, Austria and more
  10. Jul 20, 2023Phase 3 study in AsthmaNCT06023589 · 231 planned · United States, Argentina, Brazil and more
  11. Jun 10, 2024Phase 3 study in AsthmaNCT06473779 · 310 enrolled · United States, Argentina, Belgium and more
  12. Nov 7, 2024Phase 3 study in RhinosinusitisNCT06706817 · 181 enrolled · United States, Bulgaria, Canada and more
  13. Mar 3, 20252 phase 3 studies in Pulmonary Disease, Chronic ObstructiveNCT06883305, NCT06878261
  14. Nov 25, 2025Phase 3 study in AsthmaNCT07363642 · 400 planned · China
  15. Mar 24, 2026Phase 3 study in Chronic Rhinosinusitis With Nasal PolypsNCT07520162 · 230 planned · China

Ahead

  1. Jan 13, 2027Primary completion: phase 3 study in RhinosinusitisNCT06706817
  2. Jun 25, 2027Primary completion: phase 3 study in AsthmaNCT06473779
  3. Feb 7, 2028Primary completion: phase 3 study in AsthmaNCT07363642
  4. Mar 1, 2028Primary completion: phase 3 study in Chronic Rhinosinusitis With Nasal PolypsNCT07520162

TargetBeta

TSLP →read by rule
“Thymic stromal lymphopoietin inhibitor; Thymic stromal lymphopoietin inhibitor”ChEMBL 37, by rule

Other programs on TSLP

ProgramCompanyFurthest phaseStudies
tilrekimigPfizerphase 311
lunsekimigSanofiphase 310
felcorekibartGlaxoSmithKlinephase 39
SHR-1905Jiangsu HengRui Medicinephase 37
TQC2731Sino Biopharmaceuticalphase 37
WIN378rulewindward-biophase 22
CDX-622ruleCelldex Therapeuticsphase 12
HXN-1013ruleHelixon Biotechnology (Suzhou)phase 11
HY6725ruleNewsoara Biopharmaphase 11

Studies

All 28 AstraZeneca leads, newest first. Each opens its study page.

StudyPhaseStatusPrimary completionSize
NCT07520162Chronic Rhinosinusitis With Nasal Polyps · China3RecruitingMar 1, 2028230
NCT07363642Asthma · China3RecruitingFeb 7, 2028400
NCT06883305Pulmonary Disease, Chronic Obstructive · United States, Brazil, Canada and more3RecruitingMar 13, 2029990
NCT06878261Pulmonary Disease, Chronic Obstructive · United States, Argentina, Australia and more3RecruitingMar 13, 2029990
NCT06706817Rhinosinusitis · United States, Bulgaria, Canada and more3Active, not recruitingJan 13, 2027181
NCT06473779Asthma · United States, Argentina, Belgium and more3Active, not recruitingJun 25, 2027310
NCT06023589Asthma · United States, Argentina, Brazil and more3RecruitingMay 31, 2028231
NCT05583227Eosinophilic Esophagitis · United States, Australia, Austria and more3Active, not recruitingJul 14, 2026368
NCT05398263Asthma · United States, Brazil, Canada and more3TerminatedMar 24, 2025125
NCT05329194Asthma · United States4CompletedOct 1, 2025286
NCT05274815Asthma · United States, Argentina, Belgium and more3CompletedSep 9, 2024305
NCT05062759Moderate to Severe Asthma · United States3CompletedMar 21, 202270
NCT04851964Nasal Polyps · United States, Canada, China and more3CompletedSep 23, 2024416
NCT04673630Asthma · Hungary, South Africa, United Kingdom1CompletedSep 27, 202218
NCT04362410Healthy Subjects · China1CompletedOct 9, 202048
NCT04039113Pulmonary Disease, Chronic Obstructive · United States, Canada, Denmark and more2CompletedNov 10, 2023337
NCT03989544Asthma · Germany1CompletedDec 30, 2019315
NCT04048343Asthma · Japan3CompletedMar 18, 202165
NCT03968978Asthma · United States, Canada, Japan and more3CompletedJun 5, 2020216
NCT03927157Asthma · China, Philippines, South Korea3CompletedMay 24, 2024405
NCT03706079Asthma · United States, Argentina, Australia and more3CompletedOct 26, 2021951
NCT03688074Asthma · United States, Canada, Denmark and more2CompletedNov 16, 2020116
NCT03406078Asthma · United States, Argentina, Germany and more3CompletedSep 25, 2020150
NCT03347279Asthma · United States, Argentina, Australia and more3CompletedSep 8, 20201,061
NCT02525094Dermatitis, Atopic · United States, Australia, Canada and more2CompletedMay 9, 2016113
NCT02512900Asthma · Poland1CompletedMay 17, 201621
NCT02054130Asthma · United States, Bulgaria, Czechia and more2CompletedDec 12, 2016584
NCT01913028Healthy · Japan1CompletedJan 201464

How it is read

Names in the registry

  • “Tezepelumab”, 23 entries
  • “Experimental: Tezepelumab”, 4 entries
  • “MEDI9929”, 2 entries
  • “tezepelumab (Arm1&Arm2)”, 1 entry
  • “Tezepelumab Dose 1”, 1 entry

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.